Eli Lilly and Company $LLY Holdings Lessened by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 30.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,456 shares of the company’s stock after selling 635 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,685,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC raised its holdings in Eli Lilly and Company by 7.9% in the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,169.77 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The business’s 50-day simple moving average is $1,173.78 and its two-hundred day simple moving average is $1,096.45. The stock has a market cap of $1.10 trillion, a PE ratio of 39.25, a P/E/G ratio of 1.46 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the prior year, the company posted $6.31 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts forecast that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a research report on Thursday, September 17th. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Finally, Citigroup boosted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New exploratory Phase 3b data from the TOGETHER-PsO study showed that combining Taltz (ixekizumab) with Zepbound (tirzepatide) produced broader biomarker changes than Taltz alone in adults with psoriasis and obesity. The findings could strengthen Lilly’s case for using its immunology and metabolic medicines together, though the data are early and exploratory. New Phase 3b data on Lilly’s Taltz and Zepbound
• Positive Sentiment: Cantor Fitzgerald raised its price target for LLY to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s earnings growth and obesity-drug opportunity.
• Positive Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative could accelerate research, improve development efficiency and expand Lilly’s long-term pipeline. Nvidia and Eli Lilly commit to AI drug discovery lab
• Positive Sentiment: Analyst commentary continues to highlight potential growth beyond Mounjaro and Zepbound, including retatrutide, oncology products and other pipeline candidates. Retatrutide’s potential filing in 2027 provides a possible next catalyst for the obesity franchise.
• Neutral Sentiment: A technical report said Lilly recently moved above its 50-day moving average, suggesting improving short-term momentum. Technical signals may support sentiment but do not change the company’s fundamentals. Lilly overtook its 50-day moving average
• Negative Sentiment: Investors remain concerned about Lilly’s premium valuation, competition in the GLP-1 market, possible pricing pressure and the long regulatory timeline for next-generation drugs. Commentary also noted that future growth expectations are already substantial, increasing the risk of volatility if trial, regulatory or earnings results disappoint.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.